Search

Your search keyword '"D’Arminio Monforte, A."' showing total 3,264 results

Search Constraints

Start Over You searched for: Author "D’Arminio Monforte, A." Remove constraint Author: "D’Arminio Monforte, A."
3,264 results on '"D’Arminio Monforte, A."'

Search Results

251. The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study

252. Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real-Life Cohort Study

253. Recent abacavir use and incident cardiovascular disease in contemporary-treated people with HIV

255. The contribution of late HIV diagnosis on the occurrence of HIV-associated tuberculosis

256. HIV‐NAAT use for early detection of HIV infection among high‐risk men who have sex with men in Italy

258. Evaluation of HIV transmission clusters among natives and foreigners living in Italy

259. Human immunodeficiency virus continuum of care in 11 european union countries at the end of 2016 overall and by key population: Have we made progress?

260. Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data from the PRESTIGIO Registry

261. Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort

262. Virological response and retention in care according to time of starting ART in Italy: Data from the Icona Foundation Study cohort

263. Compassionate use of remdesivir for patients with severe Covid-19

264. Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepaICONA foundation cohorts

265. Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study)

266. 2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0

267. Time spent with HIV-RNA ≤ 200 copies/ml in a cohort of people with HIV during the U=U era

268. Long-term positive effect of an educational antimicrobial stewardship program implemented in an Internal Medicine Department: a prospective analysis and a point prevalence survey on long-term effect

269. A Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia

271. MO409: GDF-15 is a Predictor of Mortality in Chronic Kidney Disease Patients With Covid-19 Infection

272. Real World Estimate of Vaccination Protection in Individuals Hospitalized for COVID-19

273. Compassionate Use of Remdesivir for Patients with Severe Covid-19

274. Decrease in Incidence Rate of Hospitalizations Due to AIDS-Defining Conditions but Not to Non-AIDS Conditions in PLWHIV on cART in 2008-2018 in Italy

275. Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?

276. Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort

277. ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population

278. Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepaICONA foundation cohorts

279. Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data from the PRESTIGIO Registry

280. Evaluation of HIV transmission clusters among natives and foreigners living in Italy

281. Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort

282. Development of the HIV360 international core set of outcome measures for adults living with HIV: A consensus process.

283. An explainable model of host genetic interactions linked to COVID-19 severity

284. Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV:a multicentre prospective study from the RESPOND cohort consortium

285. CD4 T cell decline following HIV seroconversion in individuals with and without CXCR4-tropic virus

288. Changes in Cognitive Function Over 96 Weeks in Naive Patients Randomized to Darunavir–Ritonavir Plus Either Raltegravir or Tenofovir–Emtricitabine: A Substudy of the NEAT001/ANRS143 Trial

289. Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort

290. Is the rate of virological failure to cART continuing to decline in recent calendar years?

291. MO409: GDF-15 is a Predictor of Mortality in Chronic Kidney Disease Patients With Covid-19 Infection

292. Prevalence of Chagas disease and strongyloidiasis among HIV-infected Latin American immigrants in Italy – The CHILI study

293. One‐year cognitive follow‐up of COVID‐19 hospitalized patients

296. Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing

297. Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice.

298. Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy.

299. HIV Clinical Pathway: A New Approach to Combine Guidelines and Sustainability of Anti-Retroviral Treatment in Italy.

300. Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort.

Catalog

Books, media, physical & digital resources